Trial Profile
A Randomized, Double-Blind, Clinical Trial to Compare the Safety and Efficacy of Cerebrolysin and Aricept (Donepezil) and a Combination Therapy in Patients With Probable Alzheimer's Disease (AD).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Donepezil (Primary) ; FPF 1070 (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors EVER Neuro Pharma
- 08 Jul 2020 Results (n=158) published in the International Journal of Neuropsychopharmacology
- 15 Jul 2010 Results presented at the 2010 International Conference on Alzheimer's Disease and Related Disorders.
- 12 Sep 2009 Results presented at EFNS 2009.